Microbial manipulation as primary therapy for Crohn's disease

World Journal of Gastroenterology

Volumn 19, Issue 10, 2013, Pages 1513-1516

  Longman, Randy S ^a   Swaminath, Arun ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

Inflammatory bowel disease; Microbiome; Rifaximin

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; CLARITHROMYCIN; CLOFAZIMINE; DAPSONE; ETHAMBUTOL; METRONIDAZOLE; PROBIOTIC AGENT; RIFABUTIN; RIFAMPICIN; RIFAXIMIN;

ABSENCE OF SIDE EFFECTS; ANTIMICROBIAL THERAPY; ARTICLE; CROHN DISEASE; ENTERITIS; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; INFLAMMATION; INTESTINE FLORA; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION;

EID: 84875293765     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v19.i10.1513     Document Type: Article

References (19)

1. Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012; 142: 473-481.e4 [PMID: 22155172 DOI: 10.1053/j.gastro.2011.11.032]
2. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 2007; 104: 13780-13785 [PMID: 17699621]
3. Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, Järnerot G, Tysk C, Jansson JK, Engstrand L. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 2010; 139: 1844-1854.e1 [PMID: 20816835 DOI: 10.1053/j.gastro.2010.08.049]
4. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. Digestion 2006; 73 Suppl 1: 13-27 [PMID: 16498249]
5. Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SG, Berg D, Schukken Y, Scherl E, Simpson KW. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J 2007; 1: 403-418 [PMID: 18043660]
6. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez- Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci USA 2008; 105: 16731-16736 [PMID: 18936492 DOI: 10.1073/pnas.0804812105]
7. Atarashi K, Tanoue T, Shima T, Imaoka A, Kuwahara T, Momose Y, Cheng G, Yamasaki S, Saito T, Ohba Y, Taniguchi T, Takeda K, Hori S, Ivanov II, Umesaki Y, Itoh K, Honda K. Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011; 331: 337-341 [PMID: 21205640 DOI: 10.1126/science.1198469]
8. Olszak T, An D, Zeissig S, Vera MP, Richter J, Franke A, Glickman JN, Siebert R, Baron RM, Kasper DL, Blumberg RS. Microbial exposure during early life has persistent effects on natural killer T cell function. Science 2012; 336: 489-493 [PMID: 22442383 DOI: 10.1126/science.1219328]
9. Frank DN, Robertson CE, Hamm CM, Kpadeh Z, Zhang T, Chen H, Zhu W, Sartor RB, Boedeker EC, Harpaz N, Pace NR, Li E. Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 179-184 [PMID: 20839241 DOI: 10.1002/ibd.21339]
10. Ananthakrishnan AN, Binion DG. Impact of Clostridium difficile on inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2010; 4: 589-600 [PMID: 20932144 DOI: 10.1586/ egh.10.55]
11. Dogan B, Scherl E, Bosworth B, Yantiss R, Altier C, McDonough PL, Jiang ZD, Dupont HL, Garneau P, Harel J, Rishniw M, Simpson KW. Multidrug Resistance Is Common in Escherichia coli Associated with Ileal Crohn's Disease. Inflamm Bowel Dis 2013; 19: 141-150 [PMID: 22508665]
12. Afdhal NH, Long A, Lennon J, Crowe J, O'Donoghue DP. Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. Dig Dis ci 1991; 36: 449-453 [PMID: 2007362]
13. Sutherland L, Singleton J, Sessions J, Hanauer S, Krawitt E, Rankin G, Summers R, Mekhjian H, Greenberger N, Kelly M. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut 1991; 32: 1071-1075 [PMID: 1916494]
14. Prantera C, Kohn A, Mangiarotti R, Andreoli A, Luzi C. Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994; 89: 513-518 [PMID: 8147352]
15. Steinhart AH, Feagan BG, Wong CJ, Vandervoort M, Mikolainis S, Croitoru K, Seidman E, Leddin DJ, Bitton A, Drouin E, Cohen A, Greenberg GR. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial. Gastroenterology 2002; 123: 33-40 [PMID: 12105831]
16. Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm Bowel Dis 2002; 8: 10-15 [PMID: 11837933]
17. Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, Cottone M. Antibiotic treatment of Crohn' s disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006; 23: 1117-1125 [PMID: 16611272]
18. Selby W, Pavli P, Crotty B, Florin T, Radford-Smith G, Gibson P, Mitchell B, Connell W, Read R, Merrett M, Ee H, Hetzel D. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007; 132: 2313-2319 [PMID: 17570206]
19. Leiper K, Martin K, Ellis A, Watson AJ, Morris AI, Rhodes JM. Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. Aliment Pharmacol Ther 2008; 27: 1233-1239 [PMID: 18315579]